From a US commercial payer perspective, this study estimated the budget impact of vericiguat as an add-on therapy to guideline-directed medical therapy for the treatment of chronic HFrEF following a worsening HF event by integrating information from the VICTORIA trial.

At a utilization rate of 5%, 10%, and 15% for vericiguat over years 1–3, the per member per month budget impact was estimated to be $0.048, $0.064, and $0.086, respectively.

Adding vericiguat to a US commercial plan formulary was associated with limited budget impact, primarily driven by drug acquisition costs but partially offset by reduced cost of HF hospitalizations and CV deaths.